凯普生物(300639) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥183,101,224.63, a decrease of 39.39% compared to ¥302,111,598.82 in the same period last year[5]. - The net profit attributable to shareholders was -¥14,354,781.93, representing a decline of 121.96% from ¥65,353,876.62 in Q1 2023[5]. - The net cash flow from operating activities was -¥64,051,381.67, a significant drop of 192.59% compared to ¥69,178,080.03 in the previous year[5]. - Basic and diluted earnings per share were both -¥0.02, down 113.33% from ¥0.15 in the same period last year[5]. - The company reported a total operating revenue of RMB 183.10 million for Q1 2024, a decrease of 39.39% year-on-year[18]. - The net profit attributable to shareholders was a loss of RMB 14.35 million, representing a decline of 121.96% compared to the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 15.96 million, down 126.62% year-on-year[18]. - The company reported a decrease in inventory to ¥96,838,096.14 from ¥99,557,906.71, a decline of 2.7%[33]. - The net profit for Q1 2024 was -27,794,576.83 CNY, compared to a net profit of 46,306,727.49 CNY in Q1 2023, representing a significant decline[37]. - Operating profit for Q1 2024 was -31,579,832.63 CNY, down from 60,643,840.39 CNY in the same period last year[37]. - Total revenue from operating activities decreased to 266,825,264.49 CNY in Q1 2024, compared to 633,934,087.48 CNY in Q1 2023, reflecting a drop of approximately 57.96%[39]. - The company reported a total comprehensive income of -26,955,917.38 CNY for Q1 2024, compared to 19,249,083.27 CNY in Q1 2023[38]. Assets and Liabilities - Total assets at the end of Q1 2024 were ¥5,528,464,168.80, a decrease of 3.45% from ¥5,725,791,018.32 at the end of the previous year[5]. - Current assets totaled ¥2,977,276,749.66, a decrease of 6.3% from ¥3,176,925,297.43 at the beginning of the period[33]. - Cash and cash equivalents decreased to ¥640,241,504.60 from ¥764,931,888.81, representing a decline of 16.3%[33]. - Accounts receivable stood at ¥1,830,912,033.05, slightly down from ¥1,888,105,831.20, indicating a decrease of 3.1%[33]. - Total liabilities decreased to ¥484,262,537.48 from ¥627,054,734.77, a reduction of 22.8%[34]. - Total assets amounted to ¥5,528,464,168.80, down from ¥5,725,791,018.32, reflecting a decrease of 3.4%[34]. - The total cash and cash equivalents at the end of Q1 2024 were 640,241,504.60 CNY, down from 932,450,807.46 CNY at the end of Q1 2023[40]. - The company incurred a net cash outflow from investing activities of -28,097,475.91 CNY in Q1 2024, compared to -142,696,267.06 CNY in Q1 2023[40]. - The total liabilities increased, with a notable rise in financial expenses, particularly interest expenses, which were 463,532.59 CNY in Q1 2024 compared to 5,675,130.84 CNY in Q1 2023[37]. Research and Development - The company reported a 35.63% reduction in R&D expenses, totaling ¥24,295,791.99 compared to ¥37,746,736.63 in Q1 2023[11]. - The company invested RMB 28.17 million in R&D, representing 15.39% of its revenue[27]. - The company has obtained a total of 96 medical device registration certificates, including 32 Class III medical device certificates[27]. - The company has acquired 10 new invention patents during the reporting period, including 2 overseas patents[30]. - The company has developed a fully automated nucleic acid detection analysis system, enhancing its capabilities in clinical diagnostics[29]. Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 35,349[14]. - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., holds 29.88% of the shares, totaling 193,198,317 shares[14]. - The company has a total of 11,358,800 restricted shares held by executives, with 22,500 shares released during the reporting period[17]. - The total share capital has been reduced from 649,149,874 shares to 646,500,674 shares following the cancellation of repurchased shares[23]. Business Strategy and Operations - The company is focusing on three main business segments: molecular diagnostics, medical testing services, and health management, while enhancing product innovation and expanding domestic and international markets[18]. - The company is implementing cost reduction and efficiency enhancement measures to improve overall laboratory effectiveness and increase market share[19]. - The company is experiencing losses in its laboratory testing business segment, impacting the consolidated financial results[19]. - The company aims to strengthen internal management and control costs to reverse the current loss situation[19]. - The company has repurchased a total of 4,445,000 shares, accounting for 0.69% of the total share capital, with a total expenditure of RMB 30,100,843.49[21]. - The maximum and minimum repurchase prices were RMB 7.42 and RMB 5.84 per share, respectively[21]. - The company plans to use between RMB 30 million and RMB 60 million for share repurchase, with a maximum price of RMB 10.00 per share[20]. - The company has adjusted and postponed the investment amount for the nucleic acid molecular diagnostic product R&D project, increasing the investment for one entity by RMB 127.5 million[26]. - The company has extended the expected completion date for certain fundraising projects by one year while maintaining the total investment amount[26].